Models for prediction of factor VIII half-life in severe haemophiliacs: Distinct approaches for blood group O and non-O patients

PLoS ONE

Volumn 4, Issue 8, 2009, Pages

  Fischer, Kathelijn ^a,b   Pendu, Ronan ^c   van Schooten, Carina J ^b   van Dijk, Karin ^a   Denis, Cécile V ^c   van den Berg, H Marijke ^a,b   Lenting, Peter J ^b,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; PLACEBO; PROTEIN PRECURSOR; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT INTERLEUKIN 11; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR PROPEPTIDE;

ADULT; AGE DISTRIBUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD GROUP O; BODY WEIGHT; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; HALF LIFE TIME; HEMOPHILIA A; HUMAN; MOUSE; NONHUMAN; PROGNOSIS; PROTEIN BLOOD LEVEL; SURVIVAL; ADOLESCENT; ANIMAL; BLOOD; BLOOD GROUP ABO SYSTEM; C57BL MOUSE; IMMUNOLOGY; METABOLISM; MIDDLE AGED;

ABO BLOOD-GROUP SYSTEM; ADOLESCENT; ADULT; ANIMALS; COHORT STUDIES; FACTOR VIII; HALF-LIFE; HEMOPHILIA A; HUMANS; MICE; MICE, INBRED C57BL; MIDDLE AGED; VON WILLEBRAND FACTOR; YOUNG ADULT;

EID: 69449088981     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0006745     Document Type: Article

References (30)

1. Graw J, Brackmann HH, Oldenburg J, Schneppenheim R, Spannagl M, et al. (2005) Haemophilia A: from mutation analysis to new therapies. Nat Rev Genet 6: 488-501.
2. Lenting PJ, van Mourik JA, Mertens K (1998) The life cycle of coagulation factor VIII in view of its structure and function. Blood 92: 3983-3996.
3. Lenting PJ, Van Schooten CJ, Denis CV (2007) Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost 5: 1353-1360.
4. Morfini M, Mannucci PM, Tenconi PM, Longo G, Mazzucconi MG, et al. (1993) Pharmacokinetics of monoclonally-purified and recombinant factor VIII in patients with severe von Willebrand disease. Thromb Haemost 70: 270-272.
5. Berntorp E, Astermark J, Bjorkman S, Blanchette VS, Fischer K, et al. (2003) Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 9 Suppl 1:1-4:. pp 1-4.
6. Fijnvandraat K, Peters M, ten Cate JW (1995) Inter-individual variation in half-life of infused recombinant factor VIII is related to pre-infusion von Willebrand factor antigen levels. Br J Haematol 91: 474-476.
7. van Dijk K, van der Bom JG, Lenting PJ, de Groot PG, Mauser-Bunschoten EP, et al. (2005) Factor VIII half-life and clinical phenotype of severe hemophilia A. Haematologica 90: 494-498.
8. Collins PW, Blanchette VS, Fischer K, Bjorkman S, Oh M, et al. (2009) Breakthrough bleeding in relation to predicted factor VIII levels receiving prophylactic treatment for severe hemophilia A. J Thromb Haemostas 7: 413-420.
9. Vlot AJ, Mauser-Bunschoten EP, Zarkova AG, Haan E, Kruitwagen CL, et al. (2000) The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A. Thromb Haemost 83: 65-69.
10. Jenkins PV, O'Donnell JS (2006) ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? Transfusion 46: 1836-1844.
11. Borchiellini A, Fijnvandraat K, ten Cate JW, Pajkrt D, van Deventer SJ, et al. (1996) Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1- deamino-8-D-arginine vasopressin in humans. Blood 88: 2951-2958.
12. Nossent AY, Van Marion V, Van Tilburg NH, Rosendaal FR, Bertina RM, et al. (2006) von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis. J Thromb Haemost 4: 2556-2562.
13. van Mourik JA, Boertjes R, Huisveld IA, Fijnvandraat K, Pajkrt D, et al. (1999) von Willebrand factor propeptide in vascular disorders: A tool to distinguish between acute and chronic endothelial cell perturbation. Blood 94: 179-185.
14. Yarnell JW, Sweetnam PM, Rumley A, Lowe GD (2000) Lifestyle and hemostatic risk factors for ischemic heart disease: the Caerphilly Study. Arterioscler Thromb Vasc Biol 20: 271-279.
15. Fischer K, van der Bom JG, Mauser-Bunschoten EP, Roosendaal G, Prejs R, et al. (2001) Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy. Haemophilia 7: 446-452.
16. Morfini M, Lee M, Messori A (1991) The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Thromb Haemost 66: 384-386.
17. Romijn RA, Westein E, Bouma B, Schiphorst ME, Sixma JJ, et al. (2003) Mapping the Collagen-binding Site in the von Willebrand Factor-A3 Domain. J Biol Chem 278: 15035-15039.
18. VanSchooten CJ, Tjernberg P, Westein E, Terraube V, Castaman G, et al. (2005) Cysteine-mutations in von Willebrand factor associated with increased clearance. J Thromb Haemost 3: 2228-2237.
19. Denis CV, Kwack K, Saffaripour S, Maganti S, Andre P, et al. (2001) Interleukin 11 significantly increases plasma von Willebrand factor and factor VIII in wild type and von Willebrand disease mouse models. Blood 97: 465-472.
20. Lenting PJ, Westein E, Terraube V, Ribba AS, Huizinga EG, et al. (2004) An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. J Biol Chem 279: 12102-12109.
21. Van Schooten CJ, Shahbazi S, Groot E, Oortwijn BD, van den Berg HM, et al. (2008) Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood 112: 1704-1712.
22. Noe DA (1996) A mathematical model of coagulation factor VIII kinetics. Haemostasis 26: 289-303.
23. Schambeck CM, Grossmann R, Zonnur S, Berger M, Teuchert K, et al. (2004) High factor VIII (FVIII) levels in venous thromboembolism: role of unbound FVIII. Thromb Haemost 92: 42-46.
24. Olsen EH, McCain AS, Merricks EP, Fischer TH, Dillon IM, et al. (2003) Comparative response of plasma VWF in dogs to up-regulation of VWF mRNA by interleukin-11 versus Weibel-Palade body release by desmopressin (DDAVP). Blood 102: 436-441.
25. Ragni MV, Jankowitz RC, Chapman HL, Merricks EP, Kloos MT, et al. (2008) A phase II prospective open-label escalating dose trial of recombinant interleukin-11 in mild von Willebrand disease. Haemophilia 14: 968-977.
26. Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A (1977) 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet 1: 869-872.
27. Federici AB, Mazurier C, Berntorp E, Lee CA, Scharrer I, et al. (2004) Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood 103: 2032-2038.
28. McLellan DS, Knight S, McLellan HG, Wassef M, Aronstam A (1985) The influence of D.D.A.V.P. on the survival of factor VIII in severe haemophiliacs. Thromb Res 40: 113-119
29. Deitcher SR, Tuller J, Johnson JA (1999) Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients. Haemophilia 5: 88-95.
30. Fijnvandraat CJ (1998) Consequences of hemophilia treatment. Dissertation University of Amsterdam (ISBN 90-9011380-0).